|Bid||139.95 x 100|
|Ask||143.82 x 100|
|Day's Range||142.73 - 144.44|
|52 Week Range||139.36 - 209.22|
|PE Ratio (TTM)||146.50|
|Dividend & Yield||0.92 (0.66%)|
|1y Target Est||N/A|
Charlestown-based agricultural technology startup Indigo Inc. announced Monday that it is bringing on Jeff Poulton, the chief financial officer of pharmaceutical giant Shire plc, as its own CFO. Poulton will leave Shire at the end of the year, according to the Irish drugmaker. "It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company," Poulton said in a statement.
Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.